Experimental combo shows promise for tough bile duct cancer
NCT ID NCT04203160
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether adding an experimental drug called CPI-613 (devimistat) to standard chemotherapy (gemcitabine plus cisplatin) could help people with advanced biliary tract cancer that cannot be removed by surgery. The trial had two parts: first, finding the safest dose of CPI-613, then comparing the combination to chemotherapy alone. About 75 participants were planned, but the study was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CPI-613 (devimistat) plus gemcitabine and cisplatin
What this could lead to
If successful, this combination could improve response rates and delay cancer progression for people with advanced biliary tract cancer.
What could go wrong
The trial was terminated early, so results are limited. It is a small, early-phase study, and the added drug may increase side effects without clear benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allegheny Health Network
Pittsburgh, Pennsylvania, 15224, United States
-
Atlantic Health System
Morristown, New Jersey, 07960, United States
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
-
Northwestern University -- Lurie Comprehensive Cancer Center
Chicago, Illinois, 60611, United States
-
University Hospitals - Seidman Cancer Center
Cleveland, Ohio, 44106, United States
-
University of Arizona Cancer Center
Tucson, Arizona, 85724, United States
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
-
University of Texas Southwestern -- Simmons Comprehensive Cancer Center
Dallas, Texas, 75390, United States
-
University of Wisconsin - Carbone Cancer Center
Madison, Wisconsin, 53705, United States
-
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37232, United States